Skip to content
MarketScale
‹ Back to IndustriesHealthcare

HealthTech Arkansas: The Accelerator Getting MedTech Innovations Straight Into Clinics

The accelerator model is undergoing a transformation, and at the center of this change is HealthTech Arkansas, a powerful program that’s redefining the traditional approach by guaranteeing clinical pilots for healthcare startups. As the healthcare system faces a mounting burden from chronic disease (cardiovascular-related costs alone are projected to reach a staggering $1.8 trillion…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Joe Sasson · Cardiovascular InnovationClinical Pilot AccessHealthcare Startup AcceleratorHealthtech Arkansas
Share

Key takeaways

01

The accelerator model is undergoing a transformation, and at the center of this change is HealthTech Arkansas, a powerful program that’s redefining the traditional approach by guaranteeing clinical pilots for healthcare startups.

02

As the healthcare system faces a mounting burden from chronic disease (cardiovascular-related costs alone are projected to reach a staggering $1.8 trillion…

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The accelerator model is undergoing a transformation, and at the center of this change is HealthTech Arkansas, a powerful program that’s redefining the traditional approach by guaranteeing clinical pilots for healthcare startups. As the healthcare system faces a mounting burden from chronic disease (cardiovascular-related costs alone are projected to reach a staggering $1.8 trillion by 2050), the urgency for scalable, real-world innovation has never been greater.

So, how can we reshape the startup accelerator to become a true driver of innovation in patient care?

In this episode of CardioCatalyst, host Joe Sasson sits down with Jeff Stinson, Director at HealthTech Arkansas, to explore how his team is reengineering the accelerator blueprint by prioritizing clinical partnerships over pitch competitions. The conversation dives into the design, impact, and evolution of HeartX, a cardiovascular-specific initiative that connects startups directly with pilot sites and funding.

Highlights from the episode…

  • A New Model of Access: HealthTech Arkansas is the only U.S. accelerator that guarantees clinical pilots or trials for its participants, removing one of the biggest barriers for MedTech startups.
  • From Broad to Cardio-Specific: Originally industry-agnostic, the accelerator narrowed its focus in partnership with MedAxiom to create HeartX, specializing in cardiovascular innovations with national reach.
  • Clinical & Commercial Filters: Startups must demonstrate both investor-grade potential and the ability to solve real problems for healthcare providers to gain entry, ensuring only the most viable technologies make the cut.

Jeff Stinson is a seasoned early-stage investor and fund manager with over 20 years of experience leading healthcare innovation initiatives. He currently serves as Director of HealthTech Arkansas, where he designs accelerator programs that guarantee clinical engagement for MedTech startups. Jeff has also founded and led multiple entrepreneurial support organizations, including LaunchCo and Fund for Arkansas’ Future, and has directed innovation programs at the university and state levels.

Article written by MarketScale.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Joe Sasson
Joe SassonVP of Commercial Strategy

Joe Sasson is a forward-thinking and dynamic professional who has consistently remained at the forefront of commercialization, bringing a unique perspective and strategic approach to drive market growth. With a diverse background spanning marketing, operations, sales, and general management, he leverages his expertise in strategic planning and talent development to propel organizational performance to new heights.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Joe Sasson
Joe Sasson

VP of Commercial Strategy

Joe Sasson is a forward-thinking and dynamic professional who has consistently remained at the forefront of commercialization, bringing a unique perspective and strategic approach to drive market growth. With a diverse background spanning marketing, operations, sales, and general management, he leverages his expertise in strategic planning and talent development to propel organizational performance to new heights.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512